These symptoms are not always easy to spot and are commonly dismissed as signs of ageing, so all the more reason to be ...
Among patients receiving ICIs, rh-irAEs are usually moderate or severe, with more than one-third leading to ICI discontinuation.
Morning stiffness often gets dismissed as part of ageing, but persistent symptoms may sometimes indicate an underlying ...
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in combination with enfortumab vedotin (EV) has been accepted and granted Priority Review in the US for the ...